Phibro Animal Health Corporation (PAHC)
| Market Cap | 1.42B -19.9% |
| Revenue (ttm) | 1.54B +10.1% |
| Net Income | 102.71M +51.5% |
| EPS | 2.50 +49.7% |
| Shares Out | 40.60M |
| PE Ratio | 14.00 |
| Forward PE | 9.75 |
| Dividend | $0.48 (1.36%) |
| Ex-Dividend Date | Nov 25, 2026 |
| Volume | 54,407 |
| Open | 34.58 |
| Previous Close | 34.64 |
| Day's Range | 34.28 - 35.30 |
| 52-Week Range | 28.25 - 60.08 |
| Beta | 0.40 |
| Analysts | Hold |
| Price Target | 47.00 (+34.24%) |
| Earnings Date | Nov 4, 2026 |
About PAHC
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional ... [Read more]
Financial Performance
In fiscal year 2026, Phibro Animal Health's revenue was $1.52 billion, an increase of 17.12% compared to the previous year's $1.30 billion. Earnings were $99.72 million, an increase of 106.61%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for PAHC stock is "Hold." The 12-month stock price target is $47.0, which is an increase of 34.24% from the latest price.
News
Phibro Animal Health Earnings Call Transcript: Q1 2027
Q1 FY2027 sales rose 6% and adjusted EBITDA increased 4%, led by Mineral Nutrition and Performance Products. FY2027 guidance was maintained as soft producer economics and regulatory uncertainty remain.
Phibro Animal Health Quarterly report: Q1 2027
Phibro Animal Health has published its Q1 2027 quarterly earnings report on November 5, 2026.
Phibro Animal Health Earnings release: Q1 2027
Phibro Animal Health released its Q1 2027 earnings on November 5, 2026, summarizing the period's financial results.
Phibro Animal Health Slides: Q1 2027
Phibro Animal Health has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on November 5, 2026.
Phibro Animal Health reports Q1 adjusted EPS 79c, consensus 78c
Reports Q1 revenue $386.8M, one estimate $383M. “We are pleased with our start to fiscal 2027,” said Dani Bendheim, President and Chief Executive Officer of Phibro Animal Health (PAHC) Corporation.
Phibro Animal Health backs FY26 EPS view $3.41-$3.59, consensus $3.50
Backs FY26 revenue view $1.55B-$1.6B, consensus $1.58B.
Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its first quarter ended September 30, 2026 and maintai...
Phibro Animal Health Corporation Declares Quarterly Dividend
TEANECK, N.J.--(BUSINESS WIRE)--The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Cl...
Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its first quarter financial results on Wednesday, November 4, 2026, after the market closes. Phibro ...
Phibro Animal Health Proxy statement: Proxy filing
Phibro Animal Health filed a proxy statement on September 18, 2026, providing details for shareholder voting and corporate governance matters.
Phibro Animal Health Proxy statement: Proxy filing
Phibro Animal Health filed a proxy statement on September 18, 2026, providing details for shareholder voting and corporate governance matters.
Phibro Animal Health Corporation to Participate in Morgan Stanley Annual Global Healthcare Conference
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference. President & Chief Executi...
Phibro Animal Health Earnings Call Transcript: Q4 2026
Record sales and EBITDA growth were driven by strong Animal Health and Mineral Nutrition performance, successful integration of the Zoetis MFA portfolio, and operational improvements. Fiscal 2027 guidance reflects continued growth, with minimal impact assumed from virginiamycin in Brazil and benefits from the Phibro Forward program.
Phibro Animal Health Annual report: Q4 2026
Phibro Animal Health has published its Q4 2026 annual report on August 27, 2026.
Phibro Animal Health Earnings release: Q4 2026
Phibro Animal Health released its Q4 2026 earnings on August 27, 2026, summarizing the period's financial results.
Phibro Animal Health Slides: Q4 2026
Phibro Animal Health has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on August 27, 2026.
Phibro Animal Health reports Q4 adjusted EPS 85c, consensus 73c
Reports Q4 revenue $396.7M, consensus $378.33M. “Fiscal 2026 was a year of meaningful progress for Phibro,” said Dani Bendheim, President and Chief Executive Officer of Phibro Animal Health (PAHC) Cor...
Phibro Animal Health sees FY27 adjusted EPS $3.41-$3.59, consensus $3.34
Sees FY27 revenue $1.55B-$1.6B, consensus $1.55B.
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2026...
Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its fourth quarter and fiscal year 2026 financial results on Wednesday, August 26, 2026, after the m...
Phibro Animal Health Transcript: Stifel 2026 Jaws & Paws Conference
Revised summary: Global operations and a diversified portfolio have driven strong revenue and EBITDA growth, supported by acquisitions and operational improvements. Innovation in vaccines, sustainability, and a robust R&D pipeline are expected to sustain growth, with regulatory and market shifts in Brazil and Scope 3 emissions posing challenges and opportunities.
Phibro Animal Health Corporation to Participate in Stifel Jaws & Paws Conference
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Stifel Jaws & Paws Conference. Executive Vice President, Corporate Strategy &...
Phibro Animal Health price target lowered to $44 from $62 at Citi
Citi lowered the firm’s price target on Phibro Animal Health (PAHC) to $44 from $62 and keeps a Neutral rating on the shares.
Phibro Animal Health Transcript: Bank of America Global Healthcare Conference 2026
Strong quarterly growth was driven by broad portfolio performance and recent acquisitions, with continued margin expansion expected. Regulatory changes in Brazil will create short-term headwinds, but operational experience and new sustainability initiatives, including a carbon-negative feed additive, position the business for long-term growth.
Phibro Animal Health price target lowered to $44 from $62 at Citi
In a sector note on U.S. HealthTech & Distribution, Citi lowered the firm’s price target on Phibro Animal Health (PAHC) to $44 from $62 and keeps a Neutral rating on…